Vyome Holdings Announces Appointment of Renowned Oncologist Dr. Aditya Bardia as Senior Medical Advisor to Advance VT-1953 for Malignant Fungating Wounds Vyome Holdings, Inc. (“Vyome”) (NASDAQ: HIND), a clinical-stage healthcare holding company focused on developing innovative dermatological and supportive-care therapies…
Microsize and Schedio Group Sign Agreement to Acquire Lonza’s Micro-Macinazione Facility in Switzerland, Advancing a Transatlantic Particle Engineering Platform Microsize, a prominent contract development and manufacturing organization (CDMO) known for its leadership in particle size reduction, micronization, and advanced particle…
FDA Authorizes PADCEV® + Keytruda® Regimen for Eligible Individuals with Bladder Cancer Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503; President and CEO: Naoki Okamura, “Astellas”) announced that the U.S. Food and Drug Administration (FDA) has approved PADCEV®…
Quanterix Announces Comprehensive Board and Leadership Enhancements to Accelerate Its Next Phase of Strategic Growth Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX), a global leader in ultrasensitive biomarker detection and a pioneer in translating biomarker discoveries into impactful diagnostic…
BeOne Medicines Announces Positive Phase 3 HERIZON-GEA-01 Results Supporting ZIIHERA®-Based Regimens as Transformative First-Line Options for HER2-Positive Gastroesophageal Adenocarcinoma BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company committed to developing innovative therapies for hard-to-treat cancers,…
KaliVir Immunotherapeutics Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate VET3-TGI in Combination with Atezolizumab (Tecentriq®) in Advanced Solid Tumors KaliVir Immunotherapeutics, Inc., a clinical-stage biotechnology company advancing next-generation, multi-mechanistic oncolytic immunotherapies, today announced a significant clinical…
Arrowhead Pharmaceuticals Announces FDA Approval of REDEMPLO® (plozasiran), Marking a Major Advancement in Treatment for Familial Chylomicronemia Syndrome Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) announced a landmark achievement today with the U.S. Food and Drug Administration’s (FDA) approval of REDEMPLO® (plozasiran).…
Henlius and Organon Announce U.S. FDA Approval of POHERDY®, the First Interchangeable Pertuzumab Biosimilar in the United States Shanghai Henlius Biotech, Inc. (2696.HK) and Organon (NYSE: OGN) announced a major regulatory milestone with the U.S. Food and Drug Administration’s (FDA)…
Sonoma Biotherapeutics Announces Leadership Transition as Stephen Dilly, MBBS, PhD, Becomes President and CEO; Co-founder Jeff Bluestone, PhD, Assumes Advisory Role Sonoma Biotherapeutics, Inc., a clinical-stage biotechnology company advancing engineered regulatory T-cell (Treg) therapies for autoimmune and inflammatory diseases, announced…
Scribe Therapeutics Highlights Major ASCVD Lipid Insights at AHA 2025 Scribe Therapeutics Inc. (“Scribe”), a leading genetic medicines company engineering next-generation in vivo CRISPR-based treatments, unveiled a series of breakthrough preclinical findings across its cardiometabolic pipeline at the 2025 American…
Inflammasome Therapeutics to Collaborate with Healey & AMG Center on New ALS Treatment Study Inflammasome Therapeutics, a clinical-stage biotechnology company advancing a new category of drug candidates known as Kamuvudines for ophthalmic and neurological diseases, announced that it has signed…
Deciphera to Present Comprehensive Pipeline Data at the 2025 Connective Tissue Oncology Society (CTOS) Annual Meeting Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”) and its subsidiary Deciphera Pharmaceuticals, Inc. today announced that new and…